An interventional study of Continuous Passive Motion in Femoro Acetabular Impingement, Pain, Postoperative and Hip Labral Tear, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-10-08.
Sponsored by Ohio State University · Not applicable, Interventional, and Treatment
Among 37 studies in Femoracetabular Impingement with a site in United States — 10 open to participants now, 15 under way, 1 of them phase 3. Femoracetabular Impingement · United States.
Among the 37 studies in Femoracetabular Impingement with a site in United States, this one is the 16th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2013, is one of 18 with no phase, and was the 15th registered.
116 studies on the registry are indexed under Femoracetabular Impingement; 37 are open to participants now.
Browse Femoracetabular Impingement studies →10 of the 37 studies in Femoracetabular Impingement with a site in United States are open now. Recruiting first, the newest first:
American Hip Institute · Sites in United States
Ages 18–60
University of Missouri-Columbia · Sites in United States
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18–89
Massachusetts General Hospital · Sites in United States
Ages 18+
Rush University Medical Center · Sites in United States
Ages 18–40 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Femoracetabular Impingement studies recruiting now, 6 (32%) set no upper age limit and 11 (58%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 14 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 2 · Phase 4 6
First in 2012; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 73 across 70 interventional studies indexed under Femoracetabular Impingement.
Median enrollment 62 across the 28 interventional studies, 88 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
Ohio State University is the lead sponsor of 663 studies on the registry; 148 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
Ohio State University has 1 study filed under Femoracetabular Impingement — fewer than ten, so there is no comparison to draw.
5 of the studies in Femoracetabular Impingement with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
| NCT07037888Henry Ford Health SystemEfficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy | 2026-12 |
| NCT02664337Duke UniversityConjoint Analysis of Patient Preferences in Joint Interventions | 2027-07 |
| NCT04094701Rush University Medical CenterHip Arthroscopy Postoperative Opioid Demands | 2027-11 |
| NCT04113759Rush University Medical CenterBlood Flow Restriction Following Hip Arthroscopy | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Femoracetabular Impingement with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure whether CPM (continuous passive motion) usage improves outcomes following arthroscopic hip surgery that includes labral repair. Investigators tested the hypothesis that CPM usage reduces pain levels and pain medication use and improves function in individuals who undergo hip arthroscopy.
Subjects undergoing primary hip arthroscopy for acetabular labral repair were randomized to determine whether they would receive a CPM. Those subjects receiving a CPM were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks. The total number of pain medications and average pain scores over the two weeks, as well as Hip Outcome Score Activity of Daily Living (HOS ADL) scores at standard time points were compared via a two sample t-test and intention-to-treat analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
Device: Continuous Passive Motion
No CPM was administered to these subjects.
CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
Change in Patient Satisfaction and Functional Outcome
Hip Outcome Score Activities of Daily Living (HOS ADL) questionnaire completed at specific time points. Completion of the HOS ADL provides a score from 0 to 100, with a higher score corresponding to greater level of function. The improvement preoperative to 6 month postoperative scores was also computed.
Time frame: Baseline and 6 weeks, 12 weeks, and 6 months postoperatively
Analgesic Usage
Analgesic usage measured via the morphine-equivalent dose of consumed analgesic medications
Time frame: Initial two postoperative weeks
Pain Level
Change in pain level measured on a Likert-type scale from 0 to 10, with higher scores representing higher pain levels.
Time frame: Initial two postoperative weeks
| Milestone | CPM Used | No CPM Used |
|---|---|---|
| Started | 19 | 23 |
| Completed | 19 | 23 |
| Not completed | 0 | 0 |
Hip Outcome Score Activities of Daily Living (HOS ADL) questionnaire completed at specific time points. Completion of the HOS ADL provides a score from 0 to 100, with a higher score corresponding to greater level of function. The improvement preoperative to 6 month postoperative scores was also computed.
| units on a scale | CPM Used | No CPM Used |
|---|---|---|
| Preoperative | 64.5 ± 11.6 | 62.7 ± 15.0 |
| 6 weeks postoperative | 74.6 ± 14.8 | 72.8 ± 12.5 |
| 12 weeks postoperative | 81.1 ± 14.6 | 81.5 ± 11.4 |
| 6 months postoperative | 81.9 ± 16.4 | 82.8 ± 12.8 |
| Improvement | 17.0 ± 16.0 | 20.2 ± 15.3 |
Analgesic usage measured via the morphine-equivalent dose of consumed analgesic medications
| morphine equivalent doses | CPM Used | No CPM Used |
|---|---|---|
| Analgesic Usage | 239 ± 269 | 330 ± 227 |
Change in pain level measured on a Likert-type scale from 0 to 10, with higher scores representing higher pain levels.
| units on a scale | CPM Used | No CPM Used |
|---|---|---|
| Pain Level | 2.94 ± 2.0 | 4.23 ± 2.0 |
Collected over 6 months from operation date. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CPM Used | — | 0/19 (0%) | 0/19 (0%) |
| No CPM Used | — | 0/23 (0%) | 0/23 (0%) |
| Age, Continuous(years) | CPM Used | No CPM Used | Total |
|---|---|---|---|
| Mean | 36.2 ± 10.7 | 29.5 ± 11.1 | 32.5 ± 11.3 |
| Sex: Female, Male(Participants) | CPM Used | No CPM Used | Total |
|---|---|---|---|
| Female | 18 | 20 | 38 |
| Male | 1 | 3 | 4 |
| Race and Ethnicity Not Collected(Participants) | CPM Used | No CPM Used | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | CPM Used | No CPM Used | Total |
|---|---|---|---|
| United States | 19 | 23 | 42 |
| BMI(kg/m^2) | CPM Used | No CPM Used | Total |
|---|---|---|---|
| Mean | 27.5 ± 7.0 | 25.1 ± 4.6 | 26.2 ± 5.8 |
| Hand Dominance(Participants) | CPM Used | No CPM Used | Total |
|---|---|---|---|
| Right Handed | 11 | 13 | 24 |
| Left Handed | 8 | 10 | 18 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2013 to primary completion in Jun 2015, 28 months.
Results were first posted in Aug 2018, 3 years 1 month after primary completion.
Of 41 non-industry interventional studies with no phase under Femoracetabular Impingement, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 79. This study's 28 months is below that.
Counting every sponsor, half of 42 studies reached it within 41 months; a quarter within 28 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.